Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lung Neoplasms 21Multiple Myeloma 20Neoplasm Metastasis 18Lymphoma 16Leukemia, Myeloid, Acute 15Breast Neoplasms 14Prostatic Neoplasms 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Ovarian Neoplasms 11Melanoma 10Glioma 10Fallopian Tube Neoplasms 10Urinary Bladder Neoplasms 9Pancreatic Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Carcinoma, Renal Cell 8Medulloblastoma 7Cholangiocarcinoma 7Burkitt Lymphoma 7Small Cell Lung Carcinoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Oropharyngeal Neoplasms 6Leukemia, Lymphocytic, Chronic, B-Cell 6Leukemia, Biphenotypic, Acute 6Glioblastoma 6Endometrial Neoplasms 6Carcinosarcoma 6Uterine Cervical Neoplasms 5

Interventions

AZD 6244 7trametinib 2omipalisib 1mirdametinib 1Vincristine 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Lovastatin 1Dosage Forms 1Curcumin 1Control Groups 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neurofibromatosis 1 × Specimen Handling × Clear all
NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡